Published in Semin Cancer Biol on February 20, 2009
DNA hypomethylation in cancer cells. Epigenomics (2009) 3.71
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
CpG island hypermethylation in human astrocytomas. Cancer Res (2010) 1.57
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One (2012) 1.44
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med (2010) 1.34
Epigenomic reorganization of the clustered Hox genes in embryonic stem cells induced by retinoic acid. J Biol Chem (2010) 1.26
Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev (2011) 1.14
Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics (2013) 1.02
Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin (2012) 0.98
Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers. Genes Cancer (2011) 0.95
The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. Mol Cancer (2015) 0.92
The Pbx interaction motif of Hoxa1 is essential for its oncogenic activity. PLoS One (2011) 0.89
Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics (2010) 0.89
Lung cancer: a modified epigenome. Cell Adh Migr (2010) 0.89
Identification of DNA methylation changes associated with human gastric cancer. BMC Med Genomics (2011) 0.89
PDLIM2 regulates transcription factor activity in epithelial-to-mesenchymal transition via the COP9 signalosome. Mol Biol Cell (2013) 0.88
Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacol (2012) 0.88
Tumor-suppressive functions of leucine zipper transcription factor-like 1. Cancer Res (2010) 0.86
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev (2014) 0.85
EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci (2015) 0.85
Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. Dig Dis Sci (2011) 0.84
Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. Clin Cancer Res (2014) 0.83
The DNMT3B -579 G>T promoter polymorphism and risk of lung cancer. Exp Ther Med (2011) 0.82
Beyond the genome: epigenetic mechanisms in lung remodeling. Physiology (Bethesda) (2014) 0.81
Epigenetic regulation of the X-chromosomal macrosatellite repeat encoding for the cancer/testis gene CT47. Eur J Hum Genet (2011) 0.80
Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep (2014) 0.79
DNA Methylation and the HOXC6 Paradox in Prostate Cancer. Cancers (Basel) (2011) 0.77
Methylated-CpG Island Recovery Assay. Methods Mol Biol (2011) 0.76
Chemical exposure as etiology in developmental origin of adult onset human cancer. Front Pharmacol (2011) 0.75
Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. Prostate (2014) 0.75
Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer. Biol Proced Online (2017) 0.75
Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line. Oncol Lett (2015) 0.75
On Predicting lung cancer subtypes using 'omic' data from tumor and tumor-adjacent histologically-normal tissue. BMC Cancer (2016) 0.75
Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients. Oncotarget (2017) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A (1992) 29.51
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
CpG-rich islands and the function of DNA methylation. Nature (1986) 24.90
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet (2006) 18.08
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
High sensitivity mapping of methylated cytosines. Nucleic Acids Res (1994) 16.62
Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet (2005) 15.37
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature (2007) 11.14
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet (2006) 10.47
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
Methylation-induced repression--belts, braces, and chromatin. Cell (1999) 9.89
Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet (2007) 9.88
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
The power and the promise of DNA methylation markers. Nat Rev Cancer (2003) 9.32
Induction of tumors in mice by genomic hypomethylation. Science (2003) 8.86
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
The colorful history of active DNA demethylation. Cell (2008) 8.50
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature (2007) 8.33
Meiotic catastrophe and retrotransposon reactivation in male germ cells lacking Dnmt3L. Nature (2004) 7.57
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
DNA methylation in cancer: too much, but also too little. Oncogene (2002) 6.96
Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49
Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet (2000) 5.50
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet (2006) 4.97
DNA hypomethylation and human diseases. Biochim Biophys Acta (2006) 4.31
Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst (2001) 4.14
Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science (2006) 3.87
MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res (2006) 3.66
Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev (1993) 3.64
Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer (2005) 3.27
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer (2004) 3.10
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A (2007) 2.91
Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res (2001) 2.80
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol (2007) 2.45
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
Physical and functional interactions between the human DNMT3L protein and members of the de novo methyltransferase family. J Cell Biochem (2005) 2.27
Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A (2003) 2.25
Mutagenesis at methylated CpG sequences. Curr Top Microbiol Immunol (2006) 2.24
Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest (2005) 2.23
Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene (2007) 2.22
Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res (2006) 2.18
Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res (2007) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A (2005) 2.11
High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A (2007) 2.10
Profiling DNA methylation patterns using genomic tiling microarrays. Nat Methods (2005) 2.10
Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res (2008) 2.08
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Retracted Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene (2005) 1.91
Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol (2004) 1.91
The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol (2005) 1.76
CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res (2000) 1.73
Aging, DNA methylation and cancer. Crit Rev Oncol Hematol (1999) 1.70
A Dnmt2-like protein mediates DNA methylation in Drosophila. Development (2003) 1.61
Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene (2002) 1.61
Establishment of methylation-sensitive-representational difference analysis and isolation of hypo- and hypermethylated genomic fragments in mouse liver tumors. Proc Natl Acad Sci U S A (1997) 1.48
5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem Biophys Res Commun (1979) 1.47
CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer (2005) 1.46
Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol (2005) 1.45
MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-binding protein 2 (MBD2) and components of the NuRD complex. J Biol Chem (2004) 1.41
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res (2003) 1.38
Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci (2003) 1.38
Mystique is a new insulin-like growth factor-I-regulated PDZ-LIM domain protein that promotes cell attachment and migration and suppresses Anchorage-independent growth. Mol Biol Cell (2005) 1.36
Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32
Maintenance and regulation of DNA methylation patterns in mammals. Biochem Cell Biol (2005) 1.29
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays. J Pharmacol Exp Ther (2004) 1.27
The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene (2001) 1.17
Epigenetic gene silencing in cancer initiation and progression. Cancer Lett (2003) 1.08
MBD3L1 and MBD3L2, two new proteins homologous to the methyl-CpG-binding proteins MBD2 and MBD3: characterization of MBD3L1 as a testis-specific transcriptional repressor. Genomics (2002) 1.04
Hypomethylation of classical satellite DNA and chromosome instability in lymphoblastoid cell lines. Hum Genet (1993) 0.99
Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg (2005) 0.97
A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes. Oncogene (2002) 0.85
Premalignant evolution of lung cancer: Gilles F Filley lecture. Chest (2004) 0.77
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res (2011) 2.36
Insulin gene expression is regulated by DNA methylation. PLoS One (2009) 1.97
CpG island hypermethylation in human astrocytomas. Cancer Res (2010) 1.57
A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer (2010) 1.14
Chromosome-wide analysis of parental allele-specific chromatin and DNA methylation. Mol Cell Biol (2011) 1.11
CTCF-dependent chromatin bias constitutes transient epigenetic memory of the mother at the H19-Igf2 imprinting control region in prospermatogonia. PLoS Genet (2010) 1.07
Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One (2010) 1.06
Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses. Am J Pathol (2011) 0.95
Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med (2014) 0.86
Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. Arthritis Rheum (2012) 0.84
Non-MHC risk alleles in rheumatoid arthritis and in the syntenic chromosome regions of corresponding animal models. Clin Dev Immunol (2012) 0.79
Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum (2013) 0.78
Methylated-CpG island recovery assay-assisted microarrays for cancer diagnosis. Expert Opin Med Diagn (2007) 0.75